Valeo Pharma (TSE:VPH) reports quarterly earnings results

Valeo Pharma ( TSE:VPH – Get Free Report ) released its quarterly earnings data on Thursday. The company reported earnings per share (EPS) of C ($0.08) for the quarter missed consensus estimates of C ($0.05) and C ($0.03). The company had revenue of C$14.13 million for the quarter, compared to analyst expectations of C$15.50 million.

Valeo Pharma’s turnover drops by 29.0%

On Friday, Valeo Pharma shares reached CAD 0.11. The company’s 50 day simple moving average is C$0.11 and its two hundred day simple moving average is C$0.17. The company’s market capitalization is C$10.85 million, its price-to-earnings ratio is -0.34 and its beta is 2.59. Valeo Pharma has a 12 month low of C$0.06 and a 12 month high of C$0.41.

About Valeo Pharma

(Get the free report)

Valeo Pharma Inc, a specialty pharmaceutical company, acquires, brands and markets pharmaceuticals and specialty hospital products for unmet medical needs in Canada. The product portfolio includes Enerzair Breezhaler, a fixed-dose, triple-dose LABA/LAMA/ICS asthma medication; Atectura Breezhaler, a dual LABA/ICS combination asthma drug; Redesca, for the treatment and prevention of deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulfate, used to treat pain; and Yondelis, soft tissue sarcoma.

read more

Get news and ratings for Valeo Pharma every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Valeo Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.